Vivek Subbiah: Supporting Dr. Petros Grivas for the Nominating Committee in the ASCO Election for 2025
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“ASCO elections are open!
Please vote & make your vote count.
I’m delighted to support Dr. Petros Grivas for the Nominating Committee in the ASCO Election for 2025.
Dr. Grivas is a visionary leader in oncology leading practice changing trials, mentoring other faculty & trainees, director of GU Onc program Fred Hutchinson Cancer Center, graduate of ASCO leadership development program, GU cancers associate editor for patient-facing educational platform with ASCO/ACS & Member of ASCO scientific committees and ASCO ambassador.
Click here to learn more about him & the 12 other amazing candidates.
Make your vote count!”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023